Drug Profile
S 401G
Alternative Names: E2G programme; Estradiol glucoside; Oestradiol glucoside; S-401-GLatest Information Update: 16 Jul 2019
Price :
$50
*
At a glance
- Originator ProStrakan
- Class Drug conjugates; Hormonal replacements
- Mechanism of Action Estrogen receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Menopausal syndrome
Most Recent Events
- 21 Apr 2011 ProStrakan has been acquired by Kyowa Hakko Kirin
- 28 Feb 2008 Galapagos returned the Estrogen Glucoside programme back to ProStrakan
- 19 Jan 2007 Clinical development is ongoing